ID: ALA2086542

Max Phase: Preclinical

Molecular Formula: C16H23N5O5S

Molecular Weight: 397.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  C=CC(=O)Nc1ncc(S(=O)(=O)N2CCN(C(=O)OC(C)(C)C)CC2)cn1

Standard InChI:  InChI=1S/C16H23N5O5S/c1-5-13(22)19-14-17-10-12(11-18-14)27(24,25)21-8-6-20(7-9-21)15(23)26-16(2,3)4/h5,10-11H,1,6-9H2,2-4H3,(H,17,18,19,22)

Standard InChI Key:  YQDLWSGPLFKABR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 397.46

Molecular Weight (Monoisotopic): 397.1420

AlogP: 0.84

#Rotatable Bonds: 4

Polar Surface Area: 121.80

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.98

CX Basic pKa:

CX LogP: 0.52

CX LogD: 0.52

Aromatic Rings: 1

Heavy Atoms: 27

QED Weighted: 0.75

Np Likeness Score: -1.53

References

1. Prime ME, Andersen OA, Barker JJ, Brooks MA, Cheng RK, Toogood-Johnson I, Courtney SM, Brookfield FA, Yarnold CJ, Marston RW, Johnson PD, Johnsen SF, Palfrey JJ, Vaidya D, Erfan S, Ichihara O, Felicetti B, Palan S, Pedret-Dunn A, Schaertl S, Sternberger I, Ebneth A, Scheel A, Winkler D, Toledo-Sherman L, Beconi M, Macdonald D, Muñoz-Sanjuan I, Dominguez C, Wityak J..  (2012)  Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.,  55  (3): [PMID:22224594] [10.1021/jm201310y]

Source

Source(1):

• Scientific Literature